Follow-The-Filings

Security · featured owners

CRSP Crispr Therapeutics AG

Health Care NAMEN AKT Equity as of 2026 Q2 among managers we track

  • 3 Owners
  • Max 3.4%
  • $519M
  • 2 reduce

CRSP (Crispr Therapeutics AG) is held in 3 featured 13F books as of 2026 Q2. Cathie Wood - Ark Investment Management is the largest tracked holder by portfolio weight (3.4%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 3.4% (Cathie Wood - Ark Investment Management) · not free-float ownership

  1. Cathie Wood reduce 3.4%
  2. Palo Alto Investors 0.30%
  3. Murray Stahl reduce 0.01%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Cathie Wood - Ark Investment Management 2026 Q2 3.4% Reduce −16.4% 9,460,939 $516M history
Palo Alto Investors 2026 Q2 0.30% Hold 39,605 $2M history
Murray Stahl - Horizon Kinetics Asset Management 2026 Q2 0.01% Reduce −4.5% 9,353 $510K history

3 current · options excluded

SEC filings

Recent issuer filings from EDGAR · 10 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,5.03,5.07,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEFA14A Filing Doc
8-K 1.01,2.03,3.02,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 7 rows shown

Filed Form Detail Links
4 Period Aug 7, 2026 Filing Doc
4 Period Jun 5, 2026 · 10 forms Filing Doc
4 Period May 29, 2026 · 3 forms Filing Doc
4 Period May 28, 2026 Filing Doc
4 Period Mar 20, 2026 · 4 forms Filing Doc
4 Period Mar 14, 2026 · 4 forms Filing Doc
4 Period Mar 10, 2026 · 2 forms Filing Doc

Updated about 1 month ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $371.21M $37.31M $3.51M
Net income -$153.61M -$366.25M -$581.6M
Net margin * -41.4% -981.5% -16569.8%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $1.91B $1.94B $1.99B
Total non-current assets * $321.49M $304.9M $279.57M
Total assets $2.23B $2.24B $2.27B
Total current liabilities $108.79M $87.78M $149.12M
Total non-current liabilities * $237.98M $222.17M $194.31M
Total equity $1.88B $1.93B $1.92B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$260.38M -$142.77M -$345.01M
Cash from investing $374.65M -$280.48M -$31.8M
Cash from financing $62.66M $331.98M $426.03M
Net change in cash $177.01M -$91.29M $49.3M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders